Loading Ticker...
You Are Here: Home » Earning Reports

Glenmark Pharma Q3 Goes Down By 46.7%; BHEL Goes Down By 10%

While Glenmark Pharmaceuticals reported that the consolidated net profit declined by 46.70% to Rs 46.11 crore from the previous year’s Rs 86.52 crore, BHEL reported a net profit of Rs.1432 crore against Rs.1412 crore in the previous quarter, during the quarter ending December 30th, 2011.

Shares of Glenmark closed at Rs 312.15 on BSE, down 0.45% from its previous close while the stock closed at Rs 245.15 on Monday, down 10.41% from its previous close on the Bombay Stock Exchange (BSE).

BHEL had an order book position of about Rs 1,46,500 crore at end of December, 2011 and by the end of the second quarter of fiscal year 2012, BHEL’s order book position was Rs 1,61,000 crore. In case of Glenmark revenue from the generics business stood at Rs 436.83 crore as compared to Rs 300.63 crore last fiscal year. The specialty formulation business registered a revenue of Rs 584.53 crore.

Sources: 1, 2

Share this post

Subscribe to our updates via e-mail or get our  RSS Feed
Enter your email address:

Other Related Stories: